Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
The antimicrobial resistance alliance recently released its third Progress Report, reflecting on collective achievements from the life sciences industry
Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
The company plans to expand their capacity to meet the needs of pharma and biotech industries
Subscribe To Our Newsletter & Stay Updated
